- Aveo Oncology (NASDAQ:AVEO) will conduct a conference call on March 6 at 8:00 am ET to discuss the results from the Phase 2 BATON-CRC study of modified FOLFOX6 in combination with tivozanib or bevacizumab (Avastin) in metastatic colorectal cancer.
- Tivozanib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor that suppresses angiogenesis and "starves" a tumor. It was being developed under a joint collaboration with Astellas Pharma that was established in February 2011, but Astellas ended the partnership ~ one year ago for strategic reasons.
- Investigators will present the results on the same day at the American Association for Cancer Research Tumor Angiogenesis and Vascular Normalization Conference in Orlando, FL.